{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:12:26Z","timestamp":1771305146146,"version":"3.50.1"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,7,1]]},"DOI":"10.1093\/jac\/dki165","type":"journal-article","created":{"date-parts":[[2005,5,20]],"date-time":"2005-05-20T00:24:54Z","timestamp":1116548694000},"page":"6-9","source":"Crossref","is-referenced-by-count":42,"title":["Current perspectives on HIV-associated lipodystrophy syndrome"],"prefix":"10.1093","volume":"56","author":[{"given":"Ana","family":"Milinkovic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esteban","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,5,19]]},"reference":[{"key":"key\n\t\t\t\t20171012171148_B1","doi-asserted-by":"crossref","unstructured":"Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS1998; 12: F51\u20138.","DOI":"10.1097\/00002030-199807000-00003"},{"key":"key\n\t\t\t\t20171012171148_B2","doi-asserted-by":"crossref","unstructured":"Heath K, Hogg RS, Chan KJ et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV\/AIDS treatment database. AIDS2001; 15: 231\u20139.","DOI":"10.1097\/00002030-200101260-00013"},{"key":"key\n\t\t\t\t20171012171148_B3","doi-asserted-by":"crossref","unstructured":"Friis-Moller N, Weber R, Reiss P et al. Cardiovascular disease risk factors in HIV patients\u2013association with antiretroviral therapy. Results from the DAD study. AIDS2003; 17: 1179\u201393.","DOI":"10.1097\/00002030-200305230-00010"},{"key":"key\n\t\t\t\t20171012171148_B4","doi-asserted-by":"crossref","unstructured":"HIV Lipodystrophy Case Definition Study Group. An objective case definition of lipodystrophy in HIV-infected adults: a case control study. Lancet2003; 361: 726\u201335.","DOI":"10.1016\/S0140-6736(03)12656-6"},{"key":"key\n\t\t\t\t20171012171148_B5","unstructured":"Grunfeld C. Basic science and metabolic disturbances. In: Program and Abstracts of the Fourteenth International AIDS Conference, Barcelona, Spain, 2002. Abstract TuOr158. IAS International AIDS Society, Geneva, Switzerland."},{"key":"key\n\t\t\t\t20171012171148_B6","unstructured":"Kotler DP. Update on Lipodystrophy. Or Is It Just Lipoatrophy? (2002) Medscape. HIV\/AIDS. http:\/\/www.medscape.com\/viewarticle\/439480?src=search (16 May 2005, date last accessed)."},{"key":"key\n\t\t\t\t20171012171148_B7","unstructured":"Gripshover B, Tien PC, Saag M et al. Lipoatrophy is the dominant feature of the lipodystrophy syndrome in HIV-infected man. In: Programs and Abstracts of the Tenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 2003. Abstract 732, p. 319. Foundation for Retrovirology and Human Health, Alexandria, VA, USA."},{"key":"key\n\t\t\t\t20171012171148_B8","doi-asserted-by":"crossref","unstructured":"Saint-Marc T, Partisani M, Poizot-Martin I et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiviral therapy: preliminary results of the LIPOCO study. AIDS2000; 14: 37\u201349.","DOI":"10.1097\/00002030-200001070-00005"},{"key":"key\n\t\t\t\t20171012171148_B9","doi-asserted-by":"crossref","unstructured":"Enzi G, Gasparo M, Biondetti PR et al. Subcutaneous and visceral fat distribution according to sex, age, and overweight, evaluated by computed tomography. Am J Clin Nutr1986; 44: 739\u201346.","DOI":"10.1093\/ajcn\/44.6.739"},{"key":"key\n\t\t\t\t20171012171148_B10","doi-asserted-by":"crossref","unstructured":"Asensi V, Martin-Roces E, Carton JA et al. Perirenal fat diameter measured by echography could be an early predictor of lipodystrophy in HIV type 1-infected patients receiving highly active antiviral therapy. Clin Infect Dis2004; 39: 240\u20137.","DOI":"10.1086\/421774"},{"key":"key\n\t\t\t\t20171012171148_B11","doi-asserted-by":"crossref","unstructured":"Martinez E, Bianchi L, Garcia MA et al. Sonographic assessment of regional fat in HIV-infected persons. Lancet2000; 356: 1412\u201313.","DOI":"10.1016\/S0140-6736(00)02850-6"},{"key":"key\n\t\t\t\t20171012171148_B12","doi-asserted-by":"crossref","unstructured":"Wanke CA. Epidemiological and clinical aspects of metabolic complications of HIV infection: the fat redistribution syndrome. AIDS1999; 13: 1287\u201393.","DOI":"10.1097\/00002030-199907300-00004"},{"key":"key\n\t\t\t\t20171012171148_B13","unstructured":"Milinkovic A, Vidal S, Bianchi L et al. Comparative assessment of objective methods for the measurement of body fat. Antivir Ther2003; 8: L63."},{"key":"key\n\t\t\t\t20171012171148_B14","doi-asserted-by":"crossref","unstructured":"Batterham M, Garsia R, Greenop P et al. Dietary intake, serum lipids, insulin resistance and body composition in the era of highly active antiretroviral therapy \u2018Diet FRS Study\u2019. AIDS2000; 14: 1839\u201343.","DOI":"10.1097\/00002030-200008180-00020"},{"key":"key\n\t\t\t\t20171012171148_B15","doi-asserted-by":"crossref","unstructured":"Roubenoff R, Weiss L, McDermott A et al. A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat distribution. AIDS1999; 13: 1373\u20135.","DOI":"10.1097\/00002030-199907300-00015"},{"key":"key\n\t\t\t\t20171012171148_B16","doi-asserted-by":"crossref","unstructured":"Smith BA, Neidig J, Nickel J et al. Aerobic exercise: effects on parameters related to fatigue, dyspnea, weight and body composition in HIV-infected adults. AIDS2001; 15: 693\u2013701.","DOI":"10.1097\/00002030-200104130-00004"},{"key":"key\n\t\t\t\t20171012171148_B17","unstructured":"Bickel M, Zangos S, Jacobi V et al. Effects of recombinant human growth hormone (r-hGH) on fat depletion and plasma lipids in HIV-1-infected patients with lipodystrophy\u2014a randomized, open-label study. In: Program and Abstracts of the Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 2005. Abstract 855, p. 384. Foundation for Retrovirology and Human Health, Alexandria, VA, USA."},{"key":"key\n\t\t\t\t20171012171148_B18","doi-asserted-by":"crossref","unstructured":"Engelson ES, Glesby MJ, Mendez D et al. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J Acquir Immune Defic Syndr2002; 30: 379\u201391.","DOI":"10.1097\/00042560-200208010-00002"},{"key":"key\n\t\t\t\t20171012171148_B19","doi-asserted-by":"crossref","unstructured":"Lo JC, Mulligan K, Noor MA et al. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J Clin Endocrin Metab2001; 86: 3480\u20137.","DOI":"10.1210\/jcem.86.8.7785"},{"key":"key\n\t\t\t\t20171012171148_B20","doi-asserted-by":"crossref","unstructured":"Martinez E, Mocroft A, Garcia-Viejo MA et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet2001; 357: 592\u20138.","DOI":"10.1016\/S0140-6736(00)04056-3"},{"key":"key\n\t\t\t\t20171012171148_B21","doi-asserted-by":"crossref","unstructured":"Lichtnestein KA, Delaney KM, Armon C et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr2003; 32: 48\u201356.","DOI":"10.1097\/00126334-200301010-00007"},{"key":"key\n\t\t\t\t20171012171148_B22","doi-asserted-by":"crossref","unstructured":"Galli M, Cozzi-Lepri A, Ridolfo AL et al. Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study. Arch Intern Med2002; 162: 2621\u20138.","DOI":"10.1001\/archinte.162.22.2621"},{"key":"key\n\t\t\t\t20171012171148_B23","doi-asserted-by":"crossref","unstructured":"Saag MS, Cahn P, Raffi F et al. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. JAMA2004; 292: 180\u20139.","DOI":"10.1001\/jama.292.2.180"},{"key":"key\n\t\t\t\t20171012171148_B24","doi-asserted-by":"crossref","unstructured":"Gallant J, Staszewski S, Pozniak AL et al. Long-term efficacy and safety of tenofovir disoproxil fumarate (TDF): a 144-week comparison versus stavudine (d4T) in antiretroviral-naive patients. JAMA2004; 292: 191\u2013201.","DOI":"10.1001\/jama.292.2.191"},{"key":"key\n\t\t\t\t20171012171148_B25","unstructured":"Walmsley S, Horban A, Jain R et al. Fosamprenavir\/ritonavir and nelfinavir have comparable effects on body fat changes in antiretroviral-naive patients: 48-week results from the SOLO study. Antivir Ther2004; 9: L37."},{"key":"key\n\t\t\t\t20171012171148_B26","doi-asserted-by":"crossref","unstructured":"Shlay JC, Visnegarwala F, Bartsch G et al. Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine. J Acquir Immune Defic Syndr2005; 38: 147\u201355.","DOI":"10.1097\/01.qai.0000143599.64234.15"},{"key":"key\n\t\t\t\t20171012171148_B27","doi-asserted-by":"crossref","unstructured":"Martinez E, Arnaiz JA, Podzamcer D et al. Substitution of nevirapine, efavirenz or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med2003; 349: 1036\u201346.","DOI":"10.1056\/NEJMoa021589"},{"key":"key\n\t\t\t\t20171012171148_B28","doi-asserted-by":"crossref","unstructured":"Carr A, Hudson J, Chau J et al. HIV protease inhibitor substitution in patients with lipodystrophy: randomised, controlled, open-label, multicentre study. AIDS2001; 15: 1811\u201322.","DOI":"10.1097\/00002030-200109280-00010"},{"key":"key\n\t\t\t\t20171012171148_B29","doi-asserted-by":"crossref","unstructured":"Martin A, Smith DE, Ringland C et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX extension study. AIDS2004; 18: 1029\u201336.","DOI":"10.1097\/00002030-200404300-00011"},{"key":"key\n\t\t\t\t20171012171148_B30","doi-asserted-by":"crossref","unstructured":"McComsey GA, Ward DJ, Hessenthaler SM et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis2004; 38: 263\u201370.","DOI":"10.1086\/380790"},{"key":"key\n\t\t\t\t20171012171148_B31","doi-asserted-by":"crossref","unstructured":"John M, McKinnon EJ, James IR et al. Randomized, controlled, 48-week study of switching stavudine and\/or protease inhibitors to combivir\/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir Immune Defic Syndr2003; 33: 29\u201333.","DOI":"10.1097\/00126334-200305010-00005"},{"key":"key\n\t\t\t\t20171012171148_B32","doi-asserted-by":"crossref","unstructured":"Moyle GJ, Baldwin C, Langroudi B et al. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr2003; 33: 22\u20138.","DOI":"10.1097\/00126334-200305010-00004"},{"key":"key\n\t\t\t\t20171012171148_B33","unstructured":"Moyle G, Sabin C, Cartledge J et al. A 48-week, randomized, open-label comparative study of tenofovir DF vs. abacavir as substitutes for a thymidine analog in persons with lipoatrophy and sustained virological suppression on HAART. In: Program and Abstracts of the Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 2005. Abstract 44LB, p. 81. Foundation for Retrovirology and Human Health, Alexandria, VA, USA."},{"key":"key\n\t\t\t\t20171012171148_B34","unstructured":"Milinkovic A, Lopez S, Vidal S et al. A randomized open study comparing the effect of reducing stavudine dose vs. switching to tenofovir on mitochondrial function, metabolic parameters, and subcutaneous fat in HIV-infected patients receiving antiretroviral therapy containing stavudine. In: Program and Abstracts of the Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 2005. Abstract 857, p. 384. Foundation for Retrovirology and Human Health, Alexandria, VA, USA."},{"key":"key\n\t\t\t\t20171012171148_B35","unstructured":"Milinkovic A, Martinez E, Vidal S et al. Impact of structured therapy interruption on body composition of chronically HIV-infected patients: preliminary 1-year results. Antivir Ther2003; 8: L61."},{"key":"key\n\t\t\t\t20171012171148_B36","doi-asserted-by":"crossref","unstructured":"Maggiolo F, Ripamonti D, Gregis G et al. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial. AIDS2004; 18: 439\u201346.","DOI":"10.1097\/00002030-200402200-00010"},{"key":"key\n\t\t\t\t20171012171148_B37","doi-asserted-by":"crossref","unstructured":"Arioglu E, Duncan Morin J, Sebring NG. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med2000; 133: 263\u201374.","DOI":"10.7326\/0003-4819-133-4-200008150-00009"},{"key":"key\n\t\t\t\t20171012171148_B38","doi-asserted-by":"crossref","unstructured":"Petersen KF, Oral EA, Dufour S et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest2002; 109: 1345\u201350.","DOI":"10.1172\/JCI0215001"},{"key":"key\n\t\t\t\t20171012171148_B39","doi-asserted-by":"crossref","unstructured":"Oral E, Simha V, Ruiz E et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med2002; 346: 570\u20138.","DOI":"10.1056\/NEJMoa012437"},{"key":"key\n\t\t\t\t20171012171148_B40","doi-asserted-by":"crossref","unstructured":"Gelato MC, Mynarick DC, Quick JL et al. Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study. J Acquir Immune Defic Syndr2002; 31: 163\u201370.","DOI":"10.1097\/00126334-200210010-00006"},{"key":"key\n\t\t\t\t20171012171148_B41","doi-asserted-by":"crossref","unstructured":"Sutinen J, Hakkinen AM, Westerbacka J et al. Rosiglitazone in the treatment of HAART-associated lipodystrophy\u2014a randomized double-blind placebo controlled study. Antivir Ther2003; 8: 199\u2013207.","DOI":"10.1177\/135965350300800303"},{"key":"key\n\t\t\t\t20171012171148_B42","doi-asserted-by":"crossref","unstructured":"Carr A, Workman C, Carey D et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet2004; 363: 429\u201338.","DOI":"10.1016\/S0140-6736(04)15489-5"},{"key":"key\n\t\t\t\t20171012171148_B43","unstructured":"Mallon P, Sedwell GR, Rogers G et al. The effect of rosiglitazone on PPAR-\u03b3 expression in human adipose tissue is limited by continued exposure to thymidine NRTI. In: Program and Abstracts of the Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 2005. Abstract 41, p. 79. Foundation for Retrovirology and Human Health, Alexandria, VA, USA."},{"key":"key\n\t\t\t\t20171012171148_B44","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez E, Domingo P, Ribera E et al. Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors. Antivir Ther2003; 8: 403\u201310.","DOI":"10.1177\/135965350300800507"},{"key":"key\n\t\t\t\t20171012171148_B45","doi-asserted-by":"crossref","unstructured":"Hadigan C, Corcoran C, Basgoz N et al. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA. 2000; 284: 472\u20137.","DOI":"10.1001\/jama.284.4.472"},{"key":"key\n\t\t\t\t20171012171148_B46","doi-asserted-by":"crossref","unstructured":"Driscoll SD, Meininger GE, Lareau MT et al. Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients. AIDS2004; 18: 465\u201373.","DOI":"10.1097\/00002030-200402200-00013"},{"key":"key\n\t\t\t\t20171012171148_B47","doi-asserted-by":"crossref","unstructured":"Schambelan M, Benson C, Carr A et al. Management of metabolic complications associated with antiviral therapy for HIV-infection: recommendations of an International AIDS Society-USA Panel. J Acquir Immune Defic Syndr2003; 31: 257\u201375.","DOI":"10.1097\/00126334-200211010-00001"},{"key":"key\n\t\t\t\t20171012171148_B48","doi-asserted-by":"crossref","unstructured":"Ponce-De-Leon S, Iglesias M, Ceballos J et al. Liposuction for protease-inhibitor associated lipodystrophy. Lancet1999; 353: 1244.","DOI":"10.1016\/S0140-6736(99)01172-1"},{"key":"key\n\t\t\t\t20171012171148_B49","doi-asserted-by":"crossref","unstructured":"Wolfort FG, Cetrulo CL, Nevarre DR. Suction-assisted lipectomy for lipodystrophy syndromes attributed to HIV-protease inhibitor use. Plast Reconstr Surg1999; 104: 1814\u201320.","DOI":"10.1097\/00006534-199911000-00032"},{"key":"key\n\t\t\t\t20171012171148_B50","doi-asserted-by":"crossref","unstructured":"Valantin MA, Aubron-Olivier C, Ghosn J et al. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS2003; 17: 2471\u20137.","DOI":"10.1097\/00002030-200311210-00009"},{"key":"key\n\t\t\t\t20171012171148_B51","doi-asserted-by":"crossref","unstructured":"Moyle G, Lysakova L, Brown S et al. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med2004; 5: 82\u20137.","DOI":"10.1111\/j.1468-1293.2004.00190.x"},{"key":"key\n\t\t\t\t20171012171148_B52","unstructured":"US Food and Drug Administration. FDA aproves Sculptra for HIV Patients. http:\/\/www.fda.gov\/bbs\/topics\/news\/2004\/NEW01100.html (16 May 2005, date last accessed)."},{"key":"key\n\t\t\t\t20171012171148_B53","unstructured":"Ritt MJ, Hillebrand-Haverkort ME, ten Veen JH. Local treatment of facial lipodystrophy in patients receiving HIV protease inhibitor therapy. Acta Chir Plast2001; 43: 54\u20136."},{"key":"key\n\t\t\t\t20171012171148_B54","doi-asserted-by":"crossref","unstructured":"Protopopa C, Sito G, Caporale D et al. Bio-Alcamide in drug induced lipodystrophy. J Cosmet Laser Ther2003; 5: 226\u201330.","DOI":"10.1080\/14764170310021922"},{"key":"key\n\t\t\t\t20171012171148_B55","unstructured":"Guaraldi G, Orlando G, De fazio D et al. Prospective, partially randomized, 24-week study to compare the efficacy and durability of different surgical techniques and interventions for the treatment of HIV-related facial lipoatrophy. Antivir Ther2004; 9: L9."},{"key":"key\n\t\t\t\t20171012171148_B56","unstructured":"Fontdevilla J, Milinkovic A, Martinez E et al Treatment of facial lipoatrophy by injection of autologous adipose tissue. Antivir Ther2003; 8: L76."},{"key":"key\n\t\t\t\t20171012171148_B57","doi-asserted-by":"crossref","unstructured":"Serra-Renom JM, Fontdevila J. Treatment of facial fat atrophy related to treatment with protease inhibitors by autologous fat injection in patients with human immunodeficiency virus infection. Plast Reconstr Surg2004; 114: 551\u20135.","DOI":"10.1097\/01.PRS.0000128427.54445.63"},{"key":"key\n\t\t\t\t20171012171148_B58","doi-asserted-by":"crossref","unstructured":"Guaraldi G, De Fazio D, Orlando G et al. Facial lipohypertrophy in HIV-infected subjects who underwent autologous fat tissue transplantation. Clin Infect Dis2005; 40: 13\u20135.","DOI":"10.1086\/426686"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/56\/1\/6\/2084872\/dki165.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T07:33:50Z","timestamp":1683099230000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/56\/1\/6\/706765\/Current-perspectives-on-HIVassociated"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5,19]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2005,5,19]]},"published-print":{"date-parts":[[2005,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dki165","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,7]]},"published":{"date-parts":[[2005,5,19]]}}}